Vijaya Diagnostic Centre Ltd. · NSE:VIJAYA
Vijaya Diagnostic Centre — Q1 FY26 Earnings Presentation
42 slides from Vijaya Diagnostic Centre's earnings presentation, Jul 28, 2025
Slide 1: Exchange filing cover letter for investor presentation
July 28, 2025 The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: VIJAYA BSE Scrip Code: 543350 Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) R
Slide 2: Q1 FY26 Earnings Presentation
Q1 FY26 Earnings Presentation July 28, 2025 Q2 & H1 FY25 Earnings Presentation, November 07, 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 4: Q1 FY26 Performance Snapshot
Q1 FY26 Performance Snapshot Strategic Expansion
Slide 5: Q1 FY26 Performance Snapshot
Q1 FY26 Performance Snapshot Financial Performance Key Metrics 1.10 Mn 3.94 Mn INR 1,881 Mn Footfall Tests Revenue from Operations INR 735 Mn | 39.1% INR 383 Mn | 20.4% 157 (1) 93% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % Geographical Contribution Wellness Share
Slide 6: Management Commentary
Management Commentary “Vijaya reported another strong financial quarter, achieving a YOY growth of 20.4%, with our Hyderabad market returning to double-digit growth this quarter. The strong performance was largely driven by volume and change in the test mix. I'm happy to state that all the new hubs
Slide 7: Key Financial Highlights – Q1 FY26
Key Financial Highlights – Q1 FY26 Revenue from Operations (INR Mn) EBITDA & EBITDA Margin % PAT & PAT Margin % 39.2% 39.8% 39.1% 40.3% 40.1% 20.1% 20.0% 20.4% 21.7% 21.0% 6,814 5,478 2,732 Key 1,431 2,209 1,188 Financials 1,562 1,732 1,881 612 689 735 313 346 383 Q1 FY25 Q4 FY25 Q1 FY26 FY24 FY25 Q
Slide 8: Key Operational Highlights
Key Operational Highlights Tests Performed (# in Mn) Footfalls (# in Mn) Tests / Footfalls (# in Mn) 4.19 3.62 14.79 3.58 3.55 3.53 11.89 3.51 3.35 3.79 3.94 0.96 1.05 1.10 3.38 Q1 FY25 Q4 FY25 Q1 FY26 FY24 FY25 Q1 FY25 Q4 FY25 Q1 FY26 FY24 FY25 Q1 FY25 Q4 FY25 Q1 FY26 FY24 FY25 Revenue per Test (IN
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement (INR Mn) Particulars Q1 FY26 Q1 FY25 Y-o-Y Q4 FY25 Q-o-Q FY25 FY24 Y-o-Y Revenue from operations 1,880.5 1,562.2 20.4% 1,732.4 8.5% 6,813.9 5,478.1 24.4% Cost of materials consumed 214.1 187.6 14.2% 221.7 -3.4% 847.6 654.4 29.5% Employee benefits expense 316.1 27
Slide 10: Key Developments
Key Developments Strategic Expansion
Slide 11: All the New Hubs are now Fully Operational
1 All the New Hubs are now Fully Operational Kolkata Krishnanagar Barasat Pune Ambegaon Kalyani Nagar Bengaluru Yelahanka HSR Layout 10
Slide 12: On Track to Commission Hubs in the Core Geography
2 On Track to Commission 2 Hubs in the Core Geography and … 1 On Track to Commission State-of-the-art Hub in Nandyal (AP) in Q2 FY26 ▪ 8,000 sq.f.t facility houses an automated lab and advanced equipment including region’s 1st 3T MRI and 80 slice CT ▪ The strategy aligns with our plan to broaden our
Slide 13: Hub in West Bengal in Q2 FY26
22 … 1 Hub in West Bengal in Q2 FY26 3 On Track to Commission State-of-the-art Hub in Kasba (WB) in Q2 FY26 ▪ 5,250+ sq.f.t facility houses advanced equipment including region’s 1st 3T MRI ▪ Kasba is a densely populated urban area, featuring several prominent hospitals and excellent connectivity 12
Slide 14: Strategic Expansion
Strategic Expansion Strategic Expansion
Slide 15: Expanding Strategically in Alignment with our Vision
Expanding Strategically in Alignment with our Vision Inorganic Expansion Strategy • Successfully acquired PH, Pune's largest B2C integrated diagnostic chain • This strategic acquisition seamlessly aligns East India Strategy with our commitment to providing top-notch healthcare services at affordable
Slide 16: Expansion Plans - Upcoming Hubs and Spokes Centres
Expansion Plans - Upcoming Hubs and Spokes Centres Tentative Timelines for Q2 FY26 Geography Count & Type Commencement 3 1 Hubs Spoke 1 Hub Q2 FY26 West Bengal 2 Hubs H2 FY26 H2 FY26 2 1 RoAPT Hubs Spoke 2 Hubs Q2 FY26 Total Upcoming FY26 Hyderabad 1 Spoke Q2 FY26 1 Spoke H2 FY26 5 2 Hubs Spokes 15
Slide 17: Company Overview
Company Overview Strategic Expansion
Slide 18: Vijaya at a Glance
Vijaya at a Glance Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 157 state-of-the-art centres spread across 27 cities & towns Evolved from a regional player to a player with presence in multiple geographies … … While retaining its core values of providing Qua
Slide 19: Our Journey
Our Journey 1981 1993 1995 2007 20032012 2005 2016 ▪ Vijaya Diagnostic Centre ▪ Became 1st Independent diagnostic ▪ Recognized as one of the Best ▪ Received investment from incorporated in Hyderabad centre in South India to offer PET CT Imaging centres in Hyderabad Karakoram Limited & Kedaara from W
Slide 20: Integrated Diagnostics Player Offering One-Stop Solution
Integrated Diagnostics Player Offering One-Stop Solution Complete Range of Diagnostic Services under One Roof Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience 38.5 61.5 % Pathology (1) % Radiology (1) 19 1.
Slide 21: Dominant Position in Telangana & AP Markets with a Strong Brand Recall
Dominant Position in Telangana & AP Markets with a Strong Brand Recall … Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets Present in Key Geographies of AP & Telangana 70 (1) % Hyderabad Revenue Contribution Nizamabad M
Slide 22: Driving Geographical Diversification through Strategic Expansion
… and Driving Geographical Diversification through Strategic Expansion Gurgaon Hyderabad Pune RoAPT West Bengal Kalaburagi Bengaluru 78% 83% 72% 70% 19% 18% 17% 14% Geographical 6% 6% Revenue Mix 2% 5% 4% 3% 2% 0% Q1 FY26 FY25 FY24 FY23 Q1 FY26 FY25 FY24 FY23 Q1 FY26 FY25 FY24 FY23 Q1 FY26 FY25 FY24
Slide 23: Boosting Accessibility with Best-in-class Online Services & Home Collections
Boosting Accessibility with Best-in-class Online Services & Home Collections Online Services Home Collections Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings Elevating Customer Experience through Home Collections Access to reports online & histo
Slide 24: Robust Technical Capabilities with State-of-the-art IT Infrastructure
Robust Technical Capabilities with State-of-the-art IT Infrastructure 38 9 Advanced Software to Manage Clinical Data CT Machines PET CT / Gamma machines 38 300+ MRI Machines Fully Integrated Radiology Radiologists, Lab Doctors & Advance Laboratory Information Systems (RIS) and Physicians Information
Slide 25: Experienced Board of Directors
Experienced Board of Directors Ms. Suprita Reddy Dr. S. Surendranath Reddy Mr. Sunil Chandra Kondapally S Geeta Reddy Managing Director & Chief Founder & Exec. Chairman Executive Director Non-Executive Director Executive Officer ✔ 40+ years of experience ✔ 22+ years of experience ✔ 35+ years of expe
Slide 26: Stellar Management Team
Stellar Management Team Ms. Suprita Reddy Mr. Sunil Chandra Dr. S. Surendranath Reddy Mr. Sai Srinivas Lanka Managing Director & Chief Kondapally Founder & Exec. Chairman Chief Technology Officer Executive Officer Executive Director ✔ 40+ years of experience ✔ 22+ years of experience ✔ 22+ years of
Slide 27: Shareholding Pattern as at 30th June, 2025
Shareholding Pattern as at 30th June, 2025 Shareholding Pattern as at 30th June, 2025 Others 3.7% FIIs 19.6% Promoter & Promoter Group 52.6% DIIs 24.1% DIIs: Mutual Funds, AIFs and QIBs FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs Others: Retail, Bodies Corp
Slide 28: Doctors Connect Program in Q1 FY26
Doctors Connect Program in Q1 FY26 Vijaya Diagnostic organised a webinar on the Biochemical investigations in female Vijaya Diagnostic organised a webinar on MR imaging in endometriosis and infertility adenomyosis 27
Slide 29: Awards & Accolades
Awards & Accolades Most Preferred Workplace for Fastest Growing Leaders 2023- Icon in Integrated Diagnostic Most Trusted Brand of India Women 2024 – 25 recognized 24 awarded at Asian business & Best Healthcare Brands’ 2025 Services by Times Health 2024-25 awarded by by Marksmen Daily Social Forum 20
Slide 30: Annexure
Annexure Strategic Expansion
Slide 31: State-of-the-art Infrastructure (1/3)
State-of-the-art Infrastructure (1/3) 30
Slide 32: State-of-the-art Infrastructure (2/3)
State-of-the-art Infrastructure (2/3) 31
Slide 33: State-of-the-art Infrastructure (3/3)
State-of-the-art Infrastructure (3/3) 32
Slide 34: Advanced Equipment in Place to Deliver High Quality Services (1/2)
Advanced Equipment in Place to Deliver High Quality Services (1/2) 33
Slide 35: Advanced Equipment in Place to Deliver High Quality Services (2/2)
Advanced Equipment in Place to Deliver High Quality Services (2/2) 34
Slide 36: Robust Operational Metrics
Robust Operational Metrics Diagnostic Centre (Nos) Footfalls (Mn) Tests Performed (Mn) 4.19 145 151 3.62 3.55 14.79 121 3.18 11.89 95 2.63 10.05 9.32 80 7.09 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Test per Footfall (Nos) Revenue per Test (INR) Revenue per Footfall
Slide 37: Consistent Financial Performance
Consistent Financial Performance (INR Mn) Revenue EBIDTA PAT CAGR:16.0% CAGR:13.3% CAGR:14.1% 6,814 2,732 5,478 2,037 2,209 1,431 4,624 4,592 1,660 1,820 1,097 1,188 3,767 845 846 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 EBIDTA Margin (%) PAT Margin (%) 22.4% 23.7%
Slide 38: Sustainable Cash Generation & Increasing Return Ratios
Sustainable Cash Generation & Increasing Return Ratios Surplus Cash CFO (1) / EBIDTA (%) (INR Mn) 2,466 2,554 90% 2,277 1,985 1,822 83% 82% 78% 77% FY21 FY22 FY23 FY 24 FY 25 FY21 FY22 FY23 FY24 FY25 RoCE Pre-Tax (2) (%) RoE (%) 32% 31% 23% 23% 25% 25% 18% 18% 22% 16% FY21 FY22 FY23 FY24 FY25 FY21 F
Slide 39: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account (INR Mn) Particulars FY21 FY22 FY23 FY24 FY25 Revenue from operations 3,767 4,624 4,592 5,478 6,814 Cost of materials consumed 571 715 589 654 848 Employee benefits expense 574 707 785 902 1,122 Other expenses 962 1,165 1,398 1,712 2,113 EBITDA 1,660 2,037 1,820 2,
Slide 40: Consolidated Balance Sheet
Consolidated Balance Sheet (INR Mn) Assets Mar-21 Mar-22 Mar-23 Mar-24 Mar-25 Equity & Liabilities Mar-21 Mar-22 Mar-23 Mar-24 Mar-25 NON-CURRENT ASSETS 3,022 4,436 5,777 7,714 9,664 EQUITY 3,592 4,695 5,466 6,599 7,993 Property, plant and equipment 1,358 1,966 2,940 3,785 4,469 Equity share capital
Slide 41: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (INR Mn) Particulars Mar-21 Mar-22 Mar-23 Mar-24 Mar-25 Cash Flow from Operating Activities Profit before Tax 1,121 1,474 1,135 1,587 1,932 Adjustment for Non-Operating Items 534 572 683 599 786 Operating Profit before Working Capital Changes 1,655 2,046 1,818 2,186
Slide 42: Thank You
Thank You For further information please contact: Mr. Dhiren Gala AGM - Strategy & Investor Relations +91 90598 93206 dhiren.g@vijayadiagnostic.in ir@vijayadiagnostic.in www.vijayadiagnostic.com Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana
Vijaya Diagnostic Centre — Q1 FY26 Earnings Presentation on 6ix